Baltic Post-marketing Program of PEGASYS (Peg Interferon Alpha-2a 40KD) in Patients With HBeAg-positive and HBeAg-negative Chronic Hepatitis B
Phase of Trial: Phase IV
Latest Information Update: 27 Oct 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 18 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
- 24 Mar 2009 Planned number of patients changed from 50 to 51 as reported by ClinicalTrials.gov record (NCT00436163).